<!DOCTYPE html>
<html class=" js flexbox flexboxlegacy canvas canvastext webgl no-touch geolocation postmessage no-websqldatabase indexeddb hashchange history draganddrop websockets rgba hsla multiplebgs backgroundsize borderimage borderradius boxshadow textshadow opacity cssanimations csscolumns cssgradients no-cssreflections csstransforms csstransforms3d csstransitions fontface generatedcontent video audio localstorage sessionstorage webworkers applicationcache svg inlinesvg smil svgclippaths" style=""><head id="header"><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/menu174.js" type="text/javascript"></script><title>
	Cervical Cancer Screening (PDQ®) - National Cancer Institute
</title><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<!-- This is to make content width follow different rules for IE7 and below -->
<!--[if lt IE 8]>
<style type="text/css">
.contentzone-defaultTemplateContentContainer{
	width: 650px !important;
	padding-right: 50px !important;
}
.cgvBody-defaultTemplateContentContainer {
	padding-right: 0 !important;
  width: auto !important;
}
ul.ctpListPageList {
	width: 400px !important;
}
</style>
<![endif]-->
<link href="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/nci.css" rel="stylesheet"><link href="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/nci-new.css" rel="stylesheet"><link href="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/nciplus.css" rel="stylesheet"><link href="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/emergency_IE.css" rel="stylesheet"><link href="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/jquery-ui-1.css" rel="stylesheet"><link href="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/print_nci.css" rel="stylesheet"><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/imgEvents.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/popEvents.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/jquery.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/jquery-widgets.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/swfobject_002.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/jquery-ui-1.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/JSLoader.js" type="text/javascript"></script><script type="text/javascript" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/foresee-trigger.js"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/jquery_002.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/jquery_004.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/sw-autocomplete.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/swfobject.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/NCIGeneralJS.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/modernizr.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/Enlarge.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/STOC.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/popEvents_002.js" type="text/javascript"></script><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/jquery_003.js" type="text/javascript"></script><link rel="canonical" href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page2"><meta name="keywords"><meta name="description" content="Expert-reviewed information summary about tests used to detect or screen for cervical cancer."><meta name="content-language" content="en"><meta name="english-linking-policy" content="http://www.cancer.gov/global/web/policies/exit"><meta name="espanol-linking-policy" content="http://www.cancer.gov/espanol/global/politicas/salida"><meta property="og:title" content="Cervical Cancer Screening (PDQ®)"><meta property="og:description" content="Expert-reviewed information summary about tests used to detect or screen for cervical cancer."><meta property="og:type" content="Website"><meta property="og:site_name" content="National Cancer Institute"><meta property="og:url" content="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page2"><meta name="twitter:card" content="summary"><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/foresee-surveydef.js" type="text/javascript"></script><link media="all" href="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/widget020.css" type="text/css" rel="stylesheet"></head>
<body id="Body1" class="pdqcancerinfosummary">
<!-- CGov Container -->
<div id="cgovContainer"> 
<!-- Language Toggle -->
<div class="languageToggle" align="right">
<div id="LangList1">
	&nbsp;&nbsp;&nbsp;<a onclick="NCIAnalytics.ClickLink(this,'Language Select Spanish');" href="http://www.cancer.gov/espanol/pdq/deteccion/cuellouterino/HealthProfessional">Español</a>
</div>
</div>
  <!-- Site Banner -->
  <div class="skip"><a title="Skip to content" href="#skiptocontent">Skip to content</a></div>
  <div id="cgvSiteBanner">
	<div class="contentid-36963 slot-item only-SI">
		
<a name="top"></a><!-- BEGIN Logo and Search container --> <div id="logoandsearchcontainer"><!-- BEGIN NCI Logo --> <div id="NCILogo"><a href="http://www.cancer.gov/"><img nopin="nopin" alt="National Cancer Institute at the National Institutes of Health" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/nci-logo-english.gif" height="82" width="352"></a></div><!-- END NCI Logo --> <!-- BEGIN Container for right side of banner --> <div id="bannerRight"><!-- BEGIN 1-800 Number --> <div id="questionsNumber"><a href="http://www.cancer.gov/global/contact" onclick="NCIAnalytics.QuestionsAboutCancerHeader(this);"><img nopin="nopin" alt="Questions About Cancer? 1-800-4-CANCER" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/banner-800-english.gif" height="47" width="281"></a></div><!-- END 1-800 Number --> <!-- BEGIN Main Search --> <div id="mainSearch"><form action="/search/results" method="post" name="siteSearchForm" onsubmit="NCIAnalytics.SiteWideSearch(this);"><label class="hidden" for="swKeyword">Search</label> <input aria-haspopup="true" aria-autocomplete="list" role="textbox" autocomplete="off" class="searchString ui-autocomplete-input" id="swKeyword" maxlength="255" name="swKeyword" onblur="bSearchBoxBool=false;" onfocus="bSearchBoxBool=true;"> <input alt="Search" class="searchSubmit" id="sitesearch" onclick="return siteSearchSubmit();" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/main-search-btn-english.gif" type="image"></form></div><!-- END Main Search --></div><!-- END Container for right side of banner --></div><!-- END Logo and Search container -->
	</div>
</div>
  <div id="cgvMainNav">
	<div class="contentid-113330 slot-item only-SI">
		<ul class="genSiteMainNav genSiteMainNavEnglish">
			<li class="first nav-item-1"><a class="first" href="http://www.cancer.gov/"><span>NCI Home</span></a></li><li class="nav-item-2"><a class="current" href="http://www.cancer.gov/cancertopics"><span>Cancer Topics</span></a></li><li class="nav-item-3"><a class="" href="http://www.cancer.gov/clinicaltrials"><span>Clinical Trials</span></a></li><li class="nav-item-4"><a class="" href="http://www.cancer.gov/statistics"><span>Cancer Statistics</span></a></li><li class="nav-item-5"><a class="" href="http://www.cancer.gov/researchandfunding"><span>Research &amp; Funding</span></a></li><li class="nav-item-6"><a class="" href="http://www.cancer.gov/newscenter"><span>News</span></a></li><li class="last nav-item-7"><a class="last" href="http://www.cancer.gov/aboutnci"><span>About NCI</span></a></li>
		</ul>
	</div>
</div>
  
  <!-- Content Header -->
  <div id="headerzone clearfix">
    <div id="cgvSlBreadcrumb">
	<div class="contentid-870117 slot-item only-SI">
		<ul class="breadcrumbs">
			<li><a href="http://www.cancer.gov/">Home</a></li><li><a href="http://www.cancer.gov/cancertopics">Cancer Topics</a></li><li class="last-breadcrumb"><a href="http://www.cancer.gov/cancertopics/pdq">PDQ®</a></li>
		</ul>
	</div>
</div> 
	<!--Page Options Bar-->
	<div class="page-options">
		<script type="text/javascript">
	var addthis_share = {
title: "Cervical Cancer Screening (PDQ®)"}
</script><script type="text/javascript">
	var addthis_config = {
ui_language: "en",
ui_508_compliant: true}
</script><div id="PageOptionsControl1">
	<ul>
		<li class="po-view-entire-document"><a title="View entire document" href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page2/AllPages"><img alt="View entire document" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/spacer.gif"></a></li><li class="po-print"><a title="Print" onclick="NCIAnalytics.PrintLink(this);" href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page2/print"><img alt="Print" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/spacer.gif"></a></li><li class="po-email"><a title="Email" href="http://www.cancer.gov/common/popUps/PopEmail.aspx?title=Cervical+Cancer+Screening+%28PDQ%c2%ae%29&amp;docurl=%2fcancertopics%2fpdq%2fscreening%2fcervical%2fHealthProfessional%2fpage2&amp;language=en&amp;a=1H564151890&amp;b=55g407" onclick="NCIAnalytics.eMailLink(this); dynPopWindow('/common/popUps/PopEmail.aspx?title=Cervical+Cancer+Screening+%28PDQ%c2%ae%29&amp;docurl=%2fcancertopics%2fpdq%2fscreening%2fcervical%2fHealthProfessional%2fpage2&amp;language=en&amp;a=1H564151890&amp;b=55g407', 'emailPopUp', 'height=525,width=492'); return false;"><img alt="Email" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/spacer.gif"></a></li><li class="po-facebook"><a class="addthis_button_facebook add_this_btn at300b" title="Facebook" onclick="NCIAnalytics.BookmarkShareClick(this);" href="#"><img alt="Facebook" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/spacer.gif"></a></li><li class="po-twitter"><a class="addthis_button_twitter add_this_btn at300b" title="Twitter" onclick="NCIAnalytics.BookmarkShareClick(this);" href="#"><img alt="Twitter" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/spacer.gif"></a></li><li class="po-googleplus"><a target="_blank" class="addthis_button_google_plusone_share add_this_btn at300b" title="Google+" onclick="NCIAnalytics.BookmarkShareClick(this);" href="http://www.addthis.com/bookmark.php?v=300&amp;winname=addthis&amp;pub=xa-4ed7cc9f006efaac&amp;source=tbx-300&amp;lng=en&amp;s=google_plusone_share&amp;u508=1&amp;url=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fpdq%2Fscreening%2Fcervical%2FHealthProfessional%2Fpage2&amp;title=Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29&amp;ate=AT-xa-4ed7cc9f006efaac/-/-/5519b14296f5690a/2&amp;frommenu=1&amp;uid=5519b142786829d4&amp;ct=1&amp;pre=http%3A%2F%2Fwww.google.com%2Furl%3Fsa%3Dt%26rct%3Dj%26q%3D%26esrc%3Ds%26source%3Dweb%26cd%3D1%26ved%3D0CB8QFjAA%26url%3Dhttp%253A%252F%252Fwww.cancer.gov%252Fcancertopics%252Fpdq%252Fscreening%252Fcervical%252FHealthProfessional%252Fpage2%26ei%3DNbEZVYv5BoanyASU2YLoDQ%26usg%3DAFQjCNE2xE9iA1JPIx9KwHTLkxALzLDgMA%26sig2%3D45cs8EhICZ_LxZ1qV4pJlA%26bvm%3Dbv.89381419%2Cd.aWw&amp;tt=0&amp;captcha_provider=nucaptcha"><img alt="Google+" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/spacer.gif"></a></li><li class="po-pinterest"><a target="_blank" class="addthis_button_pinterest_share add_this_btn at300b" title="Pinterest" onclick="NCIAnalytics.BookmarkShareClick(this);" href="#"><img alt="Pinterest" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/spacer.gif"></a></li>
	</ul>
</div><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/addthis_widget.js" type="text/javascript">

</script>
	</div>
  </div>
  <div id="cgvLanguage">
	<div class="contentid-1513 slot-item only-SI">
		<div class="language-dates">
<div class="version-language">
<ul>
<a href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/Patient">Patient</a>  |   
<b>Health Professional</b></ul>
</div>
</div>
	</div>
</div>
  <!-- Main Area --> 
  <!-- Left Navigation and Content Area -->
  <div id="mainContainer"> 
    <!-- Left Nav Column -->
    <div class="leftzone">
      
      <div id="cgvSectionNav" class="LeftNavSlot">
	<div class="contentid-909235 slot-item only-SI">
		<!-- Begin MP Nav --><div class="leftnav-shaded-box">			                <h1><a href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional">Cervical Cancer Screening (PDQ®)</a></h1>
        				    	<ul class="leftnav-shaded-box">
									<li><a href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page1">Overview</a></li>
				    			</ul>
	   			        				    	<ul class="leftnav-shaded-box">
									<li class="leftnav-on">Description of the Evidence</li>
				    			</ul>
	   			        				    	<ul class="leftnav-shaded-box">
									<li><a href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page3">Evidence of Harm</a></li>
				    			</ul>
	   			        				    	<ul class="leftnav-shaded-box">
									<li><a href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page4">Changes to This Summary (02/12/2015)</a></li>
				    			</ul>
	   			        				    	<ul class="leftnav-shaded-box">
									<li><a href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page5">Questions or Comments About This Summary</a></li>
				    			</ul>
	   			        				    	<ul class="leftnav-shaded-box">
									<li><a href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page6">About This PDQ Summary</a></li>
				    			</ul>
	   			        				    	<ul class="leftnav-shaded-box">
									<li><a href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page7">Get More Information From NCI</a></li>
				    			</ul>
	   	</div><!-- End MP Nav -->
	</div>
</div>
      <div id="cgvLeftNav" class="LeftNavSlot">
	<div class="contentid-37093 slot-item first-SI">

	</div><div class="contentid-109265 slot-item last-SI">
		<div class="leftnav-default"><h3>Popular Resources</h3><ul><li class="general-list-item">
<div class="title-and-desc">
<a href="http://www.cancer.gov/dictionary">NCI Dictionary of Cancer Terms</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="http://www.cancer.gov/drugdictionary">NCI Drug Dictionary</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="http://www.cancer.gov/clinicaltrials/search">Search for Clinical Trials</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="https://pubs.cancer.gov/ncipl/">NCI Publications</a></div>
</li>
<li class="general-list-item">
<div class="title-and-desc">
<a href="http://www.cancer.gov/espanol">Español</a></div>
</li>
</ul></div>
	</div>
</div>
      
    </div>
    <!-- End Left Nav --> 
    <!-- Main Content Area -->
    <div class="contentzone contentzone-defaultTemplateContentContainer"> <a id="skiptocontent" tabindex="1"></a>
      <div id="cgvPublicArchiveBannerSl">
	<div class="contentid-172410 slot-item only-SI">
		
	</div>
</div>
      
      
	  <div id="cgvTitle">
	<div class="contentid-1513 slot-item only-SI">
		<h1>Cervical Cancer Screening (PDQ®)</h1>
	</div>
</div>
      
      <article id="_article">
        <div id="cgvBody" class="cgvBody-defaultTemplateContentContainer">
	<div class="contentid-909235 slot-item only-SI">
		<h2 id="_8_toc">Description of the Evidence</h2><script id="sectionToc" type="text/javascript">
       $(function(){$("#_toc_section").stoc({ search: "section", start: 3, depth: 2,
          tocTitleEn: "",
          tocTitleEs: ""});});</script>	
<section id="_section_8_2" class="pdq-sections">
  <div id="_toc_section" class="pdq-on-this-page"><h3></h3><ul><li><a href="#_9_toc">Background</a><ul><li><a href="#_207_toc">Natural history, incidence, and mortality </a></li></ul></li><li><a href="#_83_toc">The Pap Test</a></li><li><a href="#_54_toc">Accuracy of the Pap Test</a></li><li><a href="#_226_toc">New Screening Technologies</a></li><li><a href="#_234_toc">Screening Women Who Have Had a Hysterectomy</a></li><li><a href="#_236_toc">Screening Interval</a></li><li><a href="#_248_toc">HPV Testing</a><ul><li><a href="#_167_toc">Triage</a></li><li><a href="#_256_toc">Primary screening</a></li></ul></li><li><a href="#_261_toc">Screening Benefit According to Age</a></li><li><a href="#_219_toc">Alternative  Screening and Treatment Strategies  in Low-resource Settings</a></li></ul></div>
  <section id="_9">
    <h3 id="_9_toc">Background</h3>
    <section id="_207">
      <h4 id="_207_toc">Natural history, incidence, and mortality </h4>
      <p id="_208" tabindex="0">In the United States in 2015, it is 
estimated that 12,900 cases of invasive cervical cancer will be 
diagnosed and that 4,100 women will die of the disease.[<a href="#section_2.1">1</a>] These rates had been improving steadily. However, from 2007 to 2011, rates
in women younger than 50 years  were stable among whites
and decreased by 3.4% per year among blacks; in women aged 50 years or
older, rates declined by 2.5% per year in whites and by 3.8% per
year in blacks. Mortality rates were
stable among women younger than 50 years but decreased by 1.1% per
year among women aged 50 years and older.[<a href="#section_2.1">1</a>]  This improvement has been attributed largely to screening with the Papanicolaou  (Pap) test.</p>
      <p id="_209" tabindex="0">Invasive squamous carcinoma of the 
cervix results from the progression of preinvasive precursor lesions 
called cervical intraepithelial neoplasia (CIN), or dysplasia.  CIN is 
histologically graded into mild dysplasia (CIN 1), moderate dysplasia 
(CIN 2), or severe dysplasia (CIN 3).  Not all of these lesions progress
 to invasive cancer; many mild and moderate lesions regress.  A further 
categorization, the Bethesda system, is based on cytologic findings: 
atypical squamous cells of undetermined significance (ASCUS) or cannot 
rule out low-grade squamous intraepithelial lesions (LSIL), LSIL 
(consisting of cytologic atypia and CIN 1), and  high-grade squamous 
intraepithelial lesions (HSIL), primarily CIN 2–3 plus carcinoma <em>in situ</em>.[<a href="#section_2.2">2</a>]</p>
      <p id="_210" tabindex="0">The rate at which invasive cancer develops from CIN is usually slow, measured in years and perhaps decades.[<a href="#section_2.3">3</a>]
 This long natural history provides the opportunity for screening to 
effectively detect this process during the preinvasive phase, thus 
allowing early treatment and cure.  Because many of these preinvasive 
lesions (especially  LSIL) would have never progressed to invasive 
cancer,[<a href="#section_2.4">4</a>-<a href="#section_2.6">6</a>]  screening also runs the risk of leading to treatment for women who do not need to be treated.</p>
      <p id="_211" tabindex="0">Human papillomavirus (HPV) is an 
oncogenic virus and the etiologic agent of cervical cancer and related 
premalignant disease. HPV is transmitted by sexual contact.  Sexually 
inactive women rarely develop cervical cancer, while sexual activity at 
an early age with multiple sexual partners is a strong risk factor.[<a href="#section_2.7">7</a>] Nearly all women with invasive cervical cancer have evidence of HPV infection.[<a href="#section_2.8">8</a>-<a href="#section_2.11">11</a>]
 Most women with HPV infection, however, never develop cervical cancer; 
thus this infection is necessary but not sufficient for development of 
cancer.[<a href="#section_2.12">12</a>]</p>
      <p id="_212" tabindex="0">Although cervical cancer mortality increases with age,[<a href="#section_2.13">13</a>]
 the prevalence of CIN is highest among women in their 20s and 30s.  
Mortality is rare among women younger than 30 years; HSIL is rare among 
women older than 65 years who have been previously screened.  About 70% 
of ASCUS and CIN 1 lesions regress within 6 years, while about 6% of CIN
 1 lesions progress to CIN 3 or worse.  In about 10% to 20% of women 
with CIN 3 lesions, the lesions progress to invasive cancer.[<a href="#section_2.3">3</a>,<a href="#section_2.6">6</a>,<a href="#section_2.14">14</a>]</p>
      <p id="_213" tabindex="0">Cervical cancer mortality is about 40% 
higher in black women younger than 65 years than in  white women of the 
same age.  Among women older than 65 years, cervical cancer mortality 
for black women is more than 150% higher than for white women.[<a href="#section_2.13">13</a>]  In either case, mortality is rare among women of any age who have regular screenings.</p>
    </section>
  </section>
  <section id="_83">
    <h3 id="_83_toc">The Pap Test</h3>
    <p id="_215" tabindex="0">The  Pap test has never been examined in a
 randomized controlled trial.  A large body of consistent observational 
data, however, supports its effectiveness in reducing mortality from 
cervical cancer.  Both incidence and mortality from cervical cancer have
 sharply decreased in a number of large populations following the 
introduction of well-run screening programs.[<a href="#section_2.15">15</a>-<a href="#section_2.18">18</a>]
 In Iceland, the mortality rate declined by 80% for more than 20 years, 
and in Finland and Sweden by 50% and 34%, respectively.[<a href="#section_2.15">15</a>,<a href="#section_2.19">19</a>]
 Similar reductions have been observed in large populations in the 
United States and Canada.  Reductions in cervical cancer incidence and 
mortality were proportional to the intensity of screening.[<a href="#section_2.15">15</a>,<a href="#section_2.19">19</a>]  Mortality in the Canadian
provinces was reduced most remarkably in British Columbia, which had screening
rates two to five times those of the other provinces.[<a href="#section_2.20">20</a>]</p>
    <p id="_217" tabindex="0">Case-control studies have found that the risk of developing invasive cervical
cancer is three to ten times greater in women who have not been screened.[<a href="#section_2.21">21</a>-<a href="#section_2.24">24</a>] 
Risk also increases with long duration following the last normal Pap test, or
similarly, with decreasing frequency of screening.[<a href="#section_2.25">25</a>,<a href="#section_2.26">26</a>]  Screening every 2 to
3 years, however, has not been found to increase significantly the risk of
finding invasive cervical cancer above the risk expected with annual
screening.[<a href="#section_2.26">26</a>,<a href="#section_2.27">27</a>]
</p>
  </section>
  <section id="_54">
    <h3 id="_54_toc">Accuracy of the Pap Test</h3>
    <p id="_224" tabindex="0">Ideally, determining the sensitivity and 
specificity of a screening test would involve a study that applies a 
“gold standard” test (such as colposcopy with appropriate biopsy) to all
 participants (whether the screening test is positive or negative). 
Sensitivity (the percentage of “true-positive” cases  that are detected 
by the screening test) and specificity (the percentage of 
"true-negative" cases that are negative by the screening test) could be 
calculated.  Such studies have rarely been done for any screening test 
for cervical cancer.  Studies that compare the Pap test with repeat Pap 
testing have found that the sensitivity of any abnormality on a single 
test for detecting high-grade lesions is 55% to 80%.[<a href="#section_2.28">28</a>,<a href="#section_2.29">29</a>]
 Because of the usual slow-growing nature of cervical cancer, the 
sensitivity of a program of regular Pap testing is likely higher.</p>
    <p id="_74" tabindex="0">To determine the sensitivity and 
specificity of the Pap smear,  both a test threshold (i.e., the point at
 which the test will be considered to be “positive”) and a 
reference-standard threshold (i.e., the point at which the reference 
standard is considered to be “positive”) must be defined.    In 
practice, ASCUS is often used as the test threshold, and CIN 1 is often 
used as the reference threshold.  This combination gives a sensitivity 
of about 68% and a specificity of about 75%.  A more appropriate test 
threshold may be LSIL, with a reference threshold of CIN 2–3.  This 
combination gives a sensitivity of 70% to 80%, with a specificity of 
about 95%.[<a href="#section_2.30">30</a>]</p>
    <p id="_225" tabindex="0">One important factor in the accuracy of 
the Pap test is the adequacy of the specimen obtained.  Adequate 
training and using  techniques such as the cytobrush may improve 
sensitivity.[<a href="#section_2.31">31</a>]</p>
  </section>
  <section id="_226">
    <h3 id="_226_toc">New Screening Technologies</h3>
    <p id="_227" tabindex="0">Newer techniques that employ liquid-based 
cytology (e.g., ThinPrep) have been developed to improve the sensitivity
 of screening.  As with the Pap test, the optimal studies to determine 
the sensitivity and specificity of these technologies have not been 
done.  Some less-than-optimal studies show that sensitivity is modestly 
higher for detecting any degree of CIN, with modestly lower 
specificity.[<a href="#section_2.32">32</a>,<a href="#section_2.33">33</a>]
   One careful study, however, showed that conventional Pap testing was 
slightly more sensitive and specific than liquid-based cytology.[<a href="#section_2.34">34</a>]</p>
    <p id="_233" tabindex="0">The evidence is also mixed about whether liquid-based techniques improve rates of test adequacy.[<a href="#section_2.32">32</a>,<a href="#section_2.33">33</a>]  One advantage of liquid-based cytology is that <a objectid="CDR0000062756#_248" href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/Page2#_248">HPV testing</a>
 can be done on the same preparation; one disadvantage is that 
liquid-based approaches are more expensive than conventional Pap 
testing.  No study has examined whether liquid-based cytology actually 
reduces the number of women dying of cervical cancer compared with 
conventional Pap testing.</p>
  </section>
  <section id="_234">
    <h3 id="_234_toc">Screening Women Who Have Had a Hysterectomy</h3>
    <p id="_235" tabindex="0">Women who have had a hysterectomy with 
removal of the cervix for benign disease rarely have important 
abnormalities found on Pap testing.  Several studies have shown that the
 rate of high-grade vaginal lesions or vaginal cancer is less than 1 in 
1,000 tests;[<a href="#section_2.35">35</a>,<a href="#section_2.36">36</a>] no study has shown that screening for vaginal cancer reduces mortality from this rare condition.  </p>
  </section>
  <section id="_236">
    <h3 id="_236_toc">Screening Interval</h3>
    <p id="_237" tabindex="0">Because cervical cancer is slow growing, 
considerable uncertainty surrounds the issue of the optimal screening 
interval.  The most direct evidence about this issue comes from a 
prospective cohort analysis of a randomized controlled trial.[<a href="#section_2.37">37</a>]
   Among 2,561 women (mean age 66.7 years) with normal Pap tests at 
baseline, 110 had an abnormal Pap test within the next 2 years.  No 
woman was found to have CIN 2–3 or invasive cancer, and only one had CIN
 1–2.  Thus the positive-predictive value (PPV) of screening 1 year 
after a negative Pap test was 0%; after 2 years, the PPV was 0.9%.  The 
authors concluded that Pap tests should not be repeated within 2 years 
of a negative test. A large (n = 332,000) prospective cohort study of 
cervical cytology and HPV DNA co-testing in U.S. women aged 30 years and
 older found that a negative Pap smear was associated with a low risk 
for developing CIN 3 or cancer (CIN 3+) for up to 5 years after the test
 (cumulative incidence of CIN 3+ at 3 and 5 years was 0.17% and 0.36%, 
respectively).[<a href="#section_2.38">38</a>]</p>
    <p id="_238" tabindex="0">A large study that included data from the 
National Breast and Cervical Cancer Early Detection Program together 
with modeling found little further mortality reduction from cervical 
cancer for screening every year as compared with screening every 3 
years.[<a href="#section_2.39">39</a>] A similar modeling study from Australia found no differences between every 2 year and every 3 year screening.[<a href="#section_2.40">40</a>]</p>
  </section>
  <section id="_248">
    <h3 id="_248_toc">HPV Testing</h3>
    <p id="_249" tabindex="0">Noninvasive cervical squamous cell 
abnormalities  are graded histologically as CIN 1, CIN 2, or CIN 3, 
according to the severity of the cell changes and the percent of the 
epithelium replaced by abnormal cell growth. CIN 3 is a reasonably 
reproducible diagnosis  and has an approximate 30% risk of developing 
into invasive cancer over many years if untreated.[<a href="#section_2.41">41</a>] CIN 2 has poor interobserver reproducibility,[<a href="#section_2.42">42</a>] and the biologic behavior is variable.[<a href="#section_2.43">43</a>]
 CIN 3 is therefore a more rigorous endpoint for clinical trials, while 
CIN 2 represents the threshold for treatment to provide an additional 
measure of safety.</p>
    <p id="_250" tabindex="0">Approximately 15 cancer-associated 
(high-risk or carcinogenic) HPV genotypes cause virtually all cases of 
cervical cancer and precursor lesions of CIN 2 and CIN 3. However, 
carcinogenic HPV infections are very common, particularly in young 
women, and the majority clear on their own within 1 to 2                
         years. Therefore, the challenge of incorporating HPV testing in
 cervical screening programs is to balance sensitivity for detection of 
CIN 2 or CIN 2+ and  to minimize the over-referral of women with 
transient HPV infections and cervical changes that are destined to 
regress.</p>
    <p id="_251" tabindex="0"> The U.S. Food and Drug Administration 
(FDA) has approved several HPV tests.  Most of these tests are based on 
the detection of DNA from one or more oncogenic types of HPV.  One test 
detects HPV RNA.  HPV testing is approved for use in two contexts: (1) 
as a second (i.e., triage) test following an equivocal cytology result 
of ASCUS; and (2) for primary screening in conjunction with cervical 
cytology for women aged 30 years and older.[<a href="#section_2.44">44</a>] Testing for low-risk HPV types does not identify women at risk for CIN 2 or 3.[<a href="#section_2.45">45</a>,<a href="#section_2.46">46</a>]</p>
    <section id="_167">
      <h4 id="_167_toc">Triage</h4>
      <p id="_258" tabindex="0">A large randomized clinical trial, the 
ASCUS/LSIL Triage Study (ALTS), demonstrated the cost-effectiveness of 
using HPV testing to clarify the risk of an ASCUS Pap result.[<a href="#section_2.47">47</a>]
   ALTS randomly assigned women with ASCUS to one of three management 
strategies: Immediate colposcopy regardless of enrollment test results, 
referral to colposcopy if the HPV test was positive or if the enrollment
 cytology was  HSIL, and referral to colposcopy only if the cytology was
 HSIL. The HPV triage strategy was as sensitive for detection of CIN 2+ 
as immediate colposcopy, while referring only about half of the women 
for the procedure. Repeat cytology with referral to colposcopy at the 
threshold of HSIL was less sensitive for CIN 3+ (60%) compared with HPV 
triage (92%); however, using a cytologic threshold of ASCUS for referral
 increased sensitivity but resulted in 72% of women with ASCUS 
undergoing colposcopy.[<a href="#section_2.48">48</a>] HPV testing is not recommended for adolescent women with ASCUS because most of these women are HPV positive.[<a href="#section_2.49">49</a>,<a href="#section_2.50">50</a>]</p>
      <p id="_255" tabindex="0">HPV DNA testing is generally not 
appropriate or clinically useful following cytology results of LSIL, 
which is more severe than ASCUS, and most of these women (84%–96%) are 
carcinogenic HPV DNA positive.[<a href="#section_2.51">51</a>] One 
exception may be to clarify the risk for postmenopausal women with 
cytologic LSIL, which is an interpretation that can be falsely positive,
 presumably due to atrophic changes.[<a href="#section_2.52">52</a>]</p>
    </section>
    <section id="_256">
      <h4 id="_256_toc">Primary screening</h4>
      <p id="_260" tabindex="0">Testing for HPV DNA as a primary 
screening test has been FDA approved only in conjunction with cervical 
cytology and only in women aged 30 years and older. Women who are 
negative by cytology and HPV testing are at extremely low risk of CIN 3+
 and therefore may be screened less often. A prospective cohort study of
 nearly 332,000 U.S. women aged 30 years  and older undergoing HPV DNA 
and cervical cytology co-testing every 3 years found that the cumulative
 incidence of CIN 3+ in women negative for both tests at baseline was 
0.047% at 3 years and 0.16% at 5 years.[<a href="#section_2.38">38</a>] 
Screening more frequently than every 3 years would not improve 
sensitivity significantly but would increase costs and overtreatment.[<a href="#section_2.53">53</a>,<a href="#section_2.54">54</a>]</p>
      <p id="_172" tabindex="0">Numerous studies have demonstrated that,
 compared with cytology, HPV DNA testing is more sensitive for 
identifying women who have CIN 2+ (range of sensitivities 84%–97%).[<a href="#section_2.32">32</a>,<a href="#section_2.55">55</a>-<a href="#section_2.60">60</a>]
 In one randomized trial using both Pap and HPV testing in random order 
among women aged 30 to 69 years, sensitivity of HPV was 95% compared 
with 55% for Pap cytology.  The combination of HPV and cytology had 100%
 sensitivity and a referral rate of 7.9%.[<a href="#section_2.56">56</a>]</p>
      <p id="_173" tabindex="0">The lower specificity of HPV DNA testing
 compared with cytology is a consideration.   Among women older than 30 
years, cytology had a specificity of 97% compared with 94% for HPV 
testing.[<a href="#section_2.56">56</a>] The specificity of HPV DNA 
testing would likely be even lower among women younger than 30 years, 
who have more transient HPV infection that is of little consequence. 
Thus, detecting such women would potentially increase the number of 
follow-up diagnostic workups. Potential approaches to minimize 
over-referral with HPV DNA testing and improve specificity include: (1) 
triage HPV-positive results with cytology [<a href="#section_2.60">60</a>] or another more specific molecular assay;[<a href="#section_2.61">61</a>]
 and (2) trigger further workup only after two sequential positive HPV 
test results because it is the persistence of carcinogenic HPV that 
confers the greatest risk of CIN 2–3.[<a href="#section_2.62">62</a>,<a href="#section_2.63">63</a>]</p>
      <p id="_195" tabindex="0">An Italian population-based randomized, 
controlled trial of HPV DNA testing versus cervical cytology performed 
at 3-year intervals in approximately 94,000 women aged 25 to 60 years 
found a statistically significant decrease in the number of invasive 
cervical cancer cases diagnosed in the HPV DNA arm at the second round 
of screening (0 cases vs. 9 cases; <em>P</em> =             .004).  
However, about 48% of individuals in the HPV DNA arm also received 
conventional cytology testing at the first screening round, making it 
impossible to discern whether the observed difference resulted from the 
use of a combined testing strategy or HPV DNA testing alone.  Of note, 
many more women in the HPV DNA arm were referred to colposcopy for 
abnormal findings than in the cytology-alone arm (4,436 women vs. 1,416 
women), prompting the authors to conclude that if the HPV DNA test is 
used as a primary screening strategy, women with positive test results 
should be triaged by cytology before referral.[<a href="#section_2.64">64</a>]</p>
      <p id="_174" tabindex="0">A study using data from a 
population-based randomized trial of cervical screening among women aged
 32 to 38 years compared 11 different screening strategies using HPV DNA
 testing and cytology. The strategy of initial screening with an HPV DNA
 test and a triage of HPV-positive results with cytology, and subsequent
 repeat HPV DNA testing after 1 year for women who were HPV positive but
 cytology negative, increased the sensitivity for detection of CIN 3+ by
 30% compared with cytology alone, and increased the total number of 
screening tests performed by only 12%.[<a href="#section_2.65">65</a>]</p>
    </section>
  </section>
  <section id="_261">
    <h3 id="_261_toc">Screening Benefit According to Age</h3>
    <p id="_262" tabindex="0"> Cervical cancer mortality,   usually 
occurring among unscreened women, increases with age,   with the maximum
 mortality for white women  between age 45  years and  70 years, and   
for black women in their 70s.[<a href="#section_2.53">53</a>,<a href="#section_2.66">66</a>] (<a href="http://consensus.nih.gov/1996/1996CervicalCancer102html.htm" title="http://consensus.nih.gov/1996/1996CervicalCancer102html.htm">Also available online</a>.)  Mortality among women with negative Pap screening is low at all ages.</p>
    <p id="_263" tabindex="0">Screening by Pap testing with associated 
diagnostic testing and treatment is effective in reducing the incidence 
of all histologies and stages of invasive cervical cancer.[<a href="#section_2.67">67</a>]
                The benefit increases with age. Whereas the odds ratio 
(OR) is  0.79 (95% CI, 0.57–1.1) among women screened at age 30 to 31 
years for developing cancer at age 35 to 39 years, it improves to 0.26 
(95% CI, 0.19–0.36) among women screened at age 52 to 54 years for 
developing cancer at age 55 to 59 years.</p>
    <p id="_264" tabindex="0">Women aged 20 years and younger are more 
likely to have Pap abnormalities leading to further testing and 
treatment (refer to the  <a objectid="CDR0000062756#_109" href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/Page3#_109">Evidence of Harm</a>
 section of this summary for more information), so forgoing Pap testing 
in these women may improve the benefit-risk balance for this 
intervention. Women in this age group have a very low risk of cervical 
cancer and a high likelihood that cervical cell abnormalities will go 
away on their own.[<a href="#section_2.68">68</a>]</p>
    <p id="_270" tabindex="0">  HSIL are rare among women older than 65 
years who have been previously screened. For women with a negative Pap 
test at age 60 years and older, the likelihood of having a new diagnosis
 of CIN 3+ on repeat screening is less than 1 in 1,000 (in some studies,
 as few as 2–6 in 10,000).[<a href="#section_2.37">37</a>]</p>
  </section>
  <section id="_219">
    <h3 id="_219_toc">Alternative  Screening and Treatment Strategies  in Low-resource Settings</h3>
    <p id="_221" tabindex="0">
Choice in methods of screening for cervical cancer in resource-limited 
countries or underserved populations has prompted the evaluation of  
one-time screen-and-treat approaches for cervical cancer screening. </p>
    <p id="_245" tabindex="0">A clustered, randomized, controlled trial 
in rural India evaluated the impact of one-time visual inspection of the
 cervix with acetic acid (VIA) and immediate colposcopy, directed 
biopsy, and cryotherapy (where indicated) on cervical cancer incidence 
and mortality in healthy women aged 30 to 59 years.[<a href="#section_2.69">69</a>]
 Fifty-seven clusters (n = 31,343 women) received the intervention, 
while 56 control clusters (n = 30,958 women) received counseling and 
education about cervical cancer screening.  After 7 years of follow-up, 
with adjustments for age, education, marital status, parity, and cluster
 design, there was a 25% relative reduction in cervical cancer incidence
 in the intervention arm compared with the control group (hazard ratio 
[HR],    0.75; 95% confidence interval [CI], 0.55–0.95).  Using the same
 adjustments, cervical cancer mortality rates demonstrated a 35% 
relative reduction in the intervention arm compared with the control 
group (HR, 0.65; 95% CI, 0.47–0.89); the age-standardized rate of death 
due to cervical cancer was 39.6 per 100,000 person-years for the 
intervention group versus 56.7 per 100,000 person-years for the control 
group.  However, the same authors have subsequently reported that HPV 
testing is superior at reducing cervical cancer mortality using the same
 cohort.[<a href="#section_2.70">70</a>]  This population was 
essentially screen naive at entry into the study and demonstrated a much
 higher overall risk for cervical cancer death (11% of the controls) 
than that observed in the U.S. population; the applicability of these 
findings to the United States and similar western health care systems is
 therefore difficult to assess. Histological diagnosis of cervical 
lesions happened after treatment had already taken place, and 
approximately 27% of patients in this trial received cryotherapy for 
lesions later determined to be nonmalignant.[<a href="#section_2.71">71</a>]</p>
    <p id="_310" tabindex="0">A second cluster-randomized trial of VIA 
screening in low socioeconomic areas of urban Mumbai, India, similarly 
demonstrated its efficacy in reducing cervical cancer mortality.  In 
this trial, primary community health workers (as opposed to medical 
personnel) were trained to provide biennial VIA screening to 75,360 
women aged 35 to 64 years.  Women with positive screening results were 
referred to a central hospital for free diagnostic confirmation 
(including Pap smear, colposcopy, and biopsy, if indicated) and 
treatment—where warranted—according to hospital protocol.  A control 
group (n = 76,178) received general cancer education.  After 12 years, 
the relative risk of dying from cervical cancer was reduced by 31% in 
the screening arm (rate ratio, 0.69; 95% CI, 0.54–0.88), corresponding 
to about 5 fewer deaths per 100,000 woman-years. Compliance with 
treatment was about 15% lower for those in the control arm, which may 
have inflated the observed mortality benefit somewhat.[<a href="#section_2.72">72</a>]</p>
    <p id="_246" tabindex="0">A study of the feasibility of single-visit
 management of high-grade cervical lesions was conducted among a 
predominantly Latina population in California.[<a href="#section_2.73">73</a>]
 Women were randomly assigned to a single-visit group (n = 1,716) in 
which the Pap test was evaluated immediately and treatment administered 
the same day for women with HSIL or atypical glandular cells of 
undetermined significance (AGUS) results; or to usual care (n = 1,805), 
with results of the Pap test provided within 2 to 4 weeks and referrals 
for treatment based on results.  The program was feasible, with a high 
degree of acceptability and results in 14 of 16 (88%) women with 
abnormal test results completing treatment by 6 months versus 10 of 19 
(53%) women in the usual care arm completing treatment by 6 months.  
Follow-up at 12 months was also higher among women in the single-visit 
group with HSIL/AGUS than among those in the usual-care arm; among all 
women, only 36% in each group had a follow-up Pap test at 1 year.</p>
    <p id="_279" tabindex="0">Self-collected HPV testing may be an 
alternative method for cervical screening in communities with limited 
access to health care providers.  A pooled analysis of cervical 
screening studies conducted in China compared sensitivity and 
specificity of self-collection of cervical specimens for  HPV DNA 
testing, physician-collected specimens for HPV testing, liquid-based 
cytology (LBC) and visual inspection of the cervix with acetic acid 
(VIA).   The study included 13,004 participants in the analysis.   Women
 had all three sampling methods; in one study included in the pooled 
analysis, all women had colposcopy and biopsies.  Of note, the women 
were instructed in the self-collection methodology by physicians, which 
likely affected the quality of specimen collection and thus the accuracy
 of the test in these studies.  Physician-collected specimen HPV DNA 
testing had the highest sensitivity 97% for CIN 2+ (95% CI, 95.2%–98.3%)
 and 97.8 for CIN 3+ (95% CI, 95.3%–99.2%).  Self-collected specimen HPV
 testing had moderate agreement with physician-collected specimen 
testing (k = 0.67). Pooled sensitivity for self-collected HPV testing 
was 86.2% for CIN 2+ (95% CI, 82.9%–89.1%) and 86.1% for CIN 3+ (95% CI,
 81.4%–90.0%).  Pooled specificity for self-collected HPV DNA testing 
was 80.7% (95% CI, 75.6%–85.8%) for CIN 2+ and 79.5% (95% CI, 
74.1%–84.8%) for CIN 3+.  The specificity of HPV testing was lowest of 
all screening modalities.  Whereas pooled sensitivity was highest for 
physician-based HPV testing, it was lowest for the VIA screening 
methods—50.3% for CIN 2+ and 55.7% for CIN 3+.  Pooled specificity was 
highest for LBC—94.0% for CIN 2+ and 92.8% for CIN 3+.[<a href="#section_2.74">74</a>]</p>
    <p id="_247" tabindex="0">A randomized trial in South Africa 
evaluated the impact on diagnosis of CIN 2+ at 6 months with a 
screen-and-treat approach with VIA and  HPV versus delayed evaluation.[<a href="#section_2.75">75</a>]
 Women underwent HPV DNA testing and VIA testing (n = 6,555) and then 
returned in 2 to 6 days and were randomly assigned to one of three 
groups to receive (1) cryotherapy if the HPV DNA test result was 
positive (n = 2,163; 473 HPV+ and 467 treated);  (2) cryotherapy if     
              the   VIA test result was positive (n = 2,227; 492 VIA+ 
and 482 treated); or (3) delayed evaluation (n = 2,165).  At 6 months, 
CIN 2+ was  diagnosed in 0.80% of women in the HPV+/cryotherapy group, 
in  2.23% of the VIA+/cryotherapy group, and in 3.55% of the delayed 
evaluation group.  Differences in the prevalence of CIN 2+  persisted 
among the subset of women evaluated at 12 months. For the secondary 
outcome of CIN 3+, prevalence of CIN 3+ lesions was low among the three 
groups but followed the same pattern (two cases in the HPV DNA group, 
three cases in the VIA group, and eight cases in the delayed evaluation 
group).</p>
  </section>
  <h3 id="stoc_h3_12">References</h3>
  <ol>
    <li id="section_2.1">American Cancer Society: Cancer Facts and Figures 2015. Atlanta, Ga: American Cancer Society, 2015. <a href="http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf" title="http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf">Available online</a> <a class="exitNotification" href="http://www.cancer.gov/global/web/policies/exit"><img title="Exit Disclaimer" alt="Exit Disclaimer" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/exit_small.png"></a>. Last accessed January 7, 2015.</li>
    <li id="section_2.2">Solomon D, Davey D, Kurman R, et al.: The 2001 
Bethesda System: terminology for reporting results of cervical cytology.
 JAMA 287 (16): 2114-9, 2002.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11966386&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11966386&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.3">Holowaty P, Miller AB, Rohan T, et al.: Natural
 history of dysplasia of the uterine cervix. J Natl Cancer Inst 91 (3): 
252-8, 1999.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10037103&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10037103&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.4">Nasiell K, Roger V, Nasiell M: Behavior of mild
 cervical dysplasia during long-term follow-up. Obstet Gynecol 67 (5): 
665-9, 1986.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3960438&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3960438&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.5">Nash JD, Burke TW, Hoskins WJ: Biologic course 
of cervical human papillomavirus infection. Obstet Gynecol 69 (2): 
160-2, 1987.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3027635&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3027635&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.6">Melnikow J, Nuovo J, Willan AR, et al.: Natural
 history of cervical squamous intraepithelial lesions: a meta-analysis. 
Obstet Gynecol 92 (4 Pt 2): 727-35, 1998.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9764690&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9764690&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.7">Berrington de González A, Green J; 
International Collaboration of Epidemiological Studies of Cervical 
Cancer: Comparison of risk factors for invasive squamous cell carcinoma 
and adenocarcinoma of the cervix: collaborative reanalysis of individual
 data on 8,097 women with squamous cell carcinoma and 1,374 women with 
adenocarcinoma from 12 epidemiological studies. Int J Cancer 120 (4): 
885-91, 2007.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17131323&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17131323&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.8">Bosch FX, Manos MM, Muñoz N, et al.: Prevalence
 of human papillomavirus in cervical cancer: a worldwide perspective. 
International biological study on cervical cancer (IBSCC) Study Group. J
 Natl Cancer Inst 87 (11): 796-802, 1995.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7791229&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7791229&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.9">Wallin KL, Wiklund F, Angström T, et al.: 
Type-specific persistence of human papillomavirus DNA before the 
development of invasive cervical cancer. N Engl J Med 341 (22): 1633-8, 
1999.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10572150&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10572150&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.10">Alani RM, Münger K: Human papillomaviruses and associated malignancies. J Clin Oncol 16 (1): 330-7, 1998.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9440761&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9440761&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.11">Walboomers JM, Jacobs MV, Manos MM, et al.: 
Human papillomavirus is a necessary cause of invasive cervical cancer 
worldwide. J Pathol 189 (1): 12-9, 1999.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10451482&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10451482&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.12">Ho GY, Bierman R, Beardsley L, et al.: Natural
 history of cervicovaginal papillomavirus infection in young women. N 
Engl J Med 338 (7): 423-8, 1998.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9459645&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9459645&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.13">Howlader N, Noone AM, Krapcho M, et al., eds.:
 SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). 
Bethesda, Md: National Cancer Institute, 2012. <a href="http://seer.cancer.gov/csr/1975_2009_pops09/" title="http://seer.cancer.gov/csr/1975_2009_pops09/">Also available online</a>. Last accessed December 15, 2014.</li>
    <li id="section_2.14">Arends MJ, Buckley CH, Wells M: Aetiology, 
pathogenesis, and pathology of cervical neoplasia. J Clin Pathol 51 (2):
 96-103, 1998.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9602680&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9602680&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.15">Lăără E, Day NE, Hakama M: Trends in mortality
 from cervical cancer in the Nordic countries: association with 
organised screening programmes. Lancet 1 (8544): 1247-9, 1987.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2884378&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2884378&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.16">Christopherson WM, Lundin FE Jr, Mendez WM, et
 al.: Cervical cancer control: a study of morbidity and mortality trends
 over a twenty-one-year period. Cancer 38 (3): 1357-66, 1976.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=953973&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=953973&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.17">Miller AB, Lindsay J, Hill GB: Mortality from 
cancer of the uterus in Canada and its relationship to screening for 
cancer of the cervix. Int J Cancer 17 (5): 602-12, 1976.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1270176&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1270176&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.18">Johannesson G, Geirsson G, Day N: The effect 
of mass screening in Iceland, 1965-74, on the incidence and mortality of
 cervical carcinoma. Int J Cancer 21 (4): 418-25, 1978.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=669847&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=669847&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.19">Sigurdsson K: Effect of organized screening on
 the risk of cervical cancer. Evaluation of screening activity in 
Iceland, 1964-1991. Int J Cancer 54 (4): 563-70, 1993.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8514448&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8514448&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.20">Benedet JL, Anderson GH, Matisic JP: A 
comprehensive program for cervical cancer detection and management. Am J
 Obstet Gynecol 166 (4): 1254-9, 1992.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1566781&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1566781&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.21">Aristizabal N, Cuello C, Correa P, et al.: The
 impact of vaginal cytology on cervical cancer risks in Cali, Colombia. 
Int J Cancer 34 (1): 5-9, 1984.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6746118&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6746118&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.22">Clarke EA, Anderson TW: Does screening by 
"Pap" smears help prevent cervical cancer? A case-control study. Lancet 2
 (8132): 1-4, 1979.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=87887&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=87887&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.23">La Vecchia C, Franceschi S, Decarli A, et al.:
 "Pap" smear and the risk of cervical neoplasia: quantitative estimates 
from a case-control study. Lancet 2 (8406): 779-82, 1984.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6148523&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6148523&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.24">Herrero R, Brinton LA, Reeves WC, et al.: 
Screening for cervical cancer in Latin America: a case-control study. 
Int J Epidemiol 21 (6): 1050-6, 1992.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1336485&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1336485&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.25">Celentano DD, Klassen AC, Weisman CS, et al.: 
Duration of relative protection of screening for cervical cancer. Prev 
Med 18 (4): 411-22, 1989.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2678092&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2678092&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.26">Screening for squamous cervical cancer: 
duration of low risk after negative results of cervical cytology and its
 implication for screening policies. IARC Working Group on evaluation of
 cervical cancer screening programmes. Br Med J (Clin Res Ed) 293 
(6548): 659-64, 1986.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3092971&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3092971&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.27">Kleinman JC, Kopstein A: Who is being screened for cervical cancer? Am J Public Health 71 (1): 73-6, 1981.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7258434&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7258434&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.28">Soost HJ, Lange HJ, Lehmacher W, et al.: The 
validation of cervical cytology. Sensitivity, specificity and predictive
 values. Acta Cytol 35 (1): 8-14, 1991 Jan-Feb.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1994641&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1994641&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.29">Benoit AG, Krepart GV, Lotocki RJ: Results of 
prior cytologic screening in patients with a diagnosis of Stage I 
carcinoma of the cervix. Am J Obstet Gynecol 148 (5): 690-4, 1984.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6702935&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6702935&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.30">Nanda K, McCrory DC, Myers ER, et al.: 
Accuracy of the Papanicolaou test in screening for and follow-up of 
cervical cytologic abnormalities: a systematic review. Ann Intern Med 
132 (10): 810-9, 2000.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10819705&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10819705&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.31">Martin-Hirsch P, Lilford R, Jarvis G, et al.: 
Efficacy of cervical-smear collection devices: a systematic review and 
meta-analysis. Lancet 354 (9192): 1763-70, 1999.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10577637&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10577637&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.32">Hartmann KE,  Hall SA, Nanda K, et al.: 
Screening for Cervical Cancer. Rockville, Md: Agency for Health Research
 and Quality, 2002. <a href="http://www.ahrq.gov/downloads/pub/prevent/pdfser/cervcanser.pdf" title="http://www.ahrq.gov/downloads/pub/prevent/pdfser/cervcanser.pdf">Available online</a>. Last accessed February   12, 2015.</li>
    <li id="section_2.33">McCrory DC, Matchar DB, Bastian L, et al.: 
Evaluation of Cervical Cytology. Rockville, Md: Agency for Health 
Research and Quality, 1999. Evidence Report/Technology Assessment No. 5.
 AHCPR Publication No. 99-E010. <a href="http://www.ncbi.nlm.nih.gov/books/NBK11840/" title="http://www.ncbi.nlm.nih.gov/books/NBK11840/">Also available online</a>.             Last accessed February     12, 2015.</li>
    <li id="section_2.34">Coste J, Cochand-Priollet B, de Cremoux P, et 
al.: Cross sectional study of conventional cervical smear, monolayer 
cytology, and human papillomavirus DNA testing for cervical cancer 
screening. BMJ 326 (7392): 733, 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12676841&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12676841&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.35">Fox J, Remington P, Layde P, et al.: The 
effect of hysterectomy on the risk of an abnormal screening Papanicolaou
 test result. Am J Obstet Gynecol 180 (5): 1104-9, 1999.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10329862&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10329862&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.36">Pearce KF, Haefner HK, Sarwar SF, et al.: 
Cytopathological findings on vaginal Papanicolaou smears after 
hysterectomy for benign gynecologic disease. N Engl J Med 335 (21): 
1559-62, 1996.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8900088&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8900088&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.37">Sawaya GF, Grady D, Kerlikowske K, et al.: The
 positive predictive value of cervical smears in previously screened 
postmenopausal women: the Heart and Estrogen/progestin Replacement Study
 (HERS). Ann Intern Med 133 (12): 942-50, 2000.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11119395&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11119395&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.38">Katki HA, Kinney WK, Fetterman B, et al.: 
Cervical cancer risk for women undergoing concurrent testing for human 
papillomavirus and cervical cytology: a population-based study in 
routine clinical practice. Lancet Oncol 12 (7): 663-72, 2011.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21684207&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21684207&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.39">Sawaya GF, McConnell KJ, Kulasingam SL, et 
al.: Risk of cervical cancer associated with extending the interval 
between cervical-cancer screenings. N Engl J Med 349 (16): 1501-9, 
2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14561792&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14561792&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.40">Creighton P, Lew JB, Clements M, et al.: 
Cervical cancer screening in Australia: modelled evaluation of the 
impact of changing the recommended interval from two to three years. BMC
 Public Health 10: 734, 2010.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21110881&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21110881&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.41">McCredie MR, Sharples KJ, Paul C, et al.: 
Natural history of cervical neoplasia and risk of invasive cancer in 
women with cervical intraepithelial neoplasia 3: a retrospective cohort 
study. Lancet Oncol 9 (5): 425-34, 2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18407790&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18407790&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.42">Stoler MH, Schiffman M; Atypical Squamous 
Cells of Undetermined Significance-Low-grade Squamous Intraepithelial 
Lesion Triage Study (ALTS) Group: Interobserver reproducibility of 
cervical cytologic and histologic interpretations: realistic estimates 
from the ASCUS-LSIL Triage Study. JAMA 285 (11): 1500-5, 2001.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11255427&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11255427&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.43">Castle PE, Schiffman M, Wheeler CM, et al.: 
Evidence for frequent regression of cervical intraepithelial 
neoplasia-grade 2. Obstet Gynecol 113 (1): 18-25, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19104355&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19104355&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.44">New Device Approval: Digene Hybrid Capture 2 
High-Risk HPV DNA Test - P890064 S009 A004 . Rockville, Md: U.S. Food 
and Drug Administration, Center for Devices and Radiological Health, 
2003. <a href="http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm082556.htm" title="http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm082556.htm">Available Online</a>.   Last accessed February 12, 2015.</li>
    <li id="section_2.45">Thomsen LT, Frederiksen K, Munk C, et al.: 
High-risk and low-risk human papillomavirus and the absolute risk of 
cervical intraepithelial neoplasia or cancer. Obstet Gynecol 123 (1): 
57-64, 2014.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24463664&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24463664&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.46">Castle PE, Hunt WC, Langsfeld E, et al.: 
Three-year risk of cervical precancer and cancer after the detection of 
low-risk human papillomavirus genotypes targeted by a commercial test. 
Obstet Gynecol 123 (1): 49-56, 2014.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24463663&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24463663&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.47">Kulasingam SL, Kim JJ, Lawrence WF, et al.: 
Cost-effectiveness analysis based on the atypical squamous cells of 
undetermined significance/low-grade squamous intraepithelial lesion 
Triage Study (ALTS). J Natl Cancer Inst 98 (2): 92-100, 2006.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16418511&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16418511&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.48">ASCUS-LSIL Traige Study (ALTS) Group: Results 
of a randomized trial on the management of cytology interpretations of 
atypical squamous cells of undetermined significance. Am J Obstet 
Gynecol 188 (6): 1383-92, 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824967&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824967&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.49">Wright TC Jr, Massad LS, Dunton CJ, et al.: 
2006 consensus guidelines for the management of women with abnormal 
cervical cancer screening tests. Am J Obstet Gynecol 197 (4): 346-55, 
2007.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17904957&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17904957&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.50">Sherman ME, Schiffman M, Cox JT, et al.: 
Effects of age and human papilloma viral load on colposcopy triage: data
 from the randomized Atypical Squamous Cells of Undetermined 
Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study 
(ALTS). J Natl Cancer Inst 94 (2): 102-7, 2002.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11792748&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11792748&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.51">ASCUS-LSIL Traige Study (ALTS) Group: A 
randomized trial on the management of low-grade squamous intraepithelial
 lesion cytology interpretations. Am J Obstet Gynecol 188 (6): 1393-400,
 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824968&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12824968&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.52">Zuna RE, Wang SS, Rosenthal DL, et al.: 
Determinants of human papillomavirus-negative, low-grade squamous 
intraepithelial lesions in the atypical squamous cells of undetermined 
significance/low-grade squamous intraepithelial lesions triage study 
(ALTS). Cancer 105 (5): 253-62, 2005.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15991244&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15991244&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.53">Saslow D, Runowicz CD, Solomon D, et al.: 
American Cancer Society guideline for the early detection of cervical 
neoplasia and cancer. CA Cancer J Clin 52 (6): 342-62, 2002 
Nov-Dec.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12469763&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12469763&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.54">Goldie SJ, Kim JJ, Wright TC: 
Cost-effectiveness of human papillomavirus DNA testing for cervical 
cancer screening in women aged 30 years or more. Obstet Gynecol 103 (4):
 619-31, 2004.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15051550&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15051550&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.55">Arbyn M, Sasieni P, Meijer CJ, et al.: Chapter
 9: Clinical applications of HPV testing: a summary of meta-analyses. 
Vaccine 24 (Suppl 3): S3/78-89, 2006.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16950021&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16950021&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.56">Mayrand MH, Duarte-Franco E, Rodrigues I, et 
al.: Human papillomavirus DNA versus Papanicolaou screening tests for 
cervical cancer. N Engl J Med 357 (16): 1579-88, 2007.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17942871&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17942871&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.57">Naucler P, Ryd W, Törnberg S, et al.: Human 
papillomavirus and Papanicolaou tests to screen for cervical cancer. N 
Engl J Med 357 (16): 1589-97, 2007.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17942872&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17942872&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.58">Bulkmans NW, Berkhof J, Rozendaal L, et al.: 
Human papillomavirus DNA testing for the detection of cervical 
intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a 
randomised controlled implementation trial. Lancet 370 (9601): 1764-72, 
2007.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17919718&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17919718&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.59">Cuzick J, Szarewski A, Cubie H, et al.: 
Management of women who test positive for high-risk types of human 
papillomavirus: the HART study. Lancet 362 (9399): 1871-6, 2003.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14667741&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14667741&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.60">Cuzick J, Clavel C, Petry KU, et al.: Overview
 of the European and North American studies on HPV testing in primary 
cervical cancer screening. Int J Cancer 119 (5): 1095-101, 2006.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16586444&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16586444&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.61">Carozzi F, Confortini M, Dalla Palma P, et 
al.: Use of p16-INK4A overexpression to increase the specificity of 
human papillomavirus testing: a nested substudy of the NTCC randomised 
controlled trial. Lancet Oncol 9 (10): 937-45, 2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18783988&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18783988&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.62">Koshiol J, Lindsay L, Pimenta JM, et al.: 
Persistent human papillomavirus infection and cervical neoplasia: a 
systematic review and meta-analysis. Am J Epidemiol 168 (2): 123-37, 
2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18483125&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18483125&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.63">Castle PE: Invited commentary: is monitoring 
of human papillomavirus infection for viral persistence ready for use in
 cervical cancer screening? Am J Epidemiol 168 (2): 138-44; discussion 
145-8, 2008.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18483124&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18483124&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.64">Ronco G, Giorgi-Rossi P, Carozzi F, et al.: 
Efficacy of human papillomavirus testing for the detection of invasive 
cervical cancers and cervical intraepithelial neoplasia: a randomised 
controlled trial. Lancet Oncol 11 (3): 249-57, 2010.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20089449&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20089449&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.65">Naucler P, Ryd W, Törnberg S, et al.: Efficacy
 of HPV DNA testing with cytology triage and/or repeat HPV DNA testing 
in primary cervical cancer screening. J Natl Cancer Inst 101 (2): 88-99,
 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19141778&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19141778&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.66">National Institutes of Health Consensus 
Development Conference Statement: cervical cancer, April 1-3, 1996. 
National Institutes of Health Consensus Development Panel. J Natl Cancer
 Inst Monogr  (21): vii-xix, 1996.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9023821&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9023821&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.67">Sasieni P, Castanon A, Cuzick J: Effectiveness
 of cervical screening with age: population based case-control study of 
prospectively recorded data. BMJ 339: b2968, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19638651&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19638651&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.68">Saslow D, Solomon D, Lawson HW, et al.: 
American Cancer Society, American Society for Colposcopy and Cervical 
Pathology, and American Society for Clinical Pathology screening 
guidelines for the prevention and early detection of cervical cancer. CA
 Cancer J Clin 62 (3): 147-72, 2012 May-Jun.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22422631&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22422631&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.69">Sankaranarayanan R, Esmy PO, Rajkumar R, et 
al.: Effect of visual screening on cervical cancer incidence and 
mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 370 
(9585): 398-406, 2007.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17679017&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17679017&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.70">Sankaranarayanan R, Nene BM, Shastri SS, et 
al.: HPV screening for cervical cancer in rural India. N Engl J Med 360 
(14): 1385-94, 2009.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19339719&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19339719&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.71">Szarewski A: Cervical screening by visual inspection with acetic acid. Lancet 370 (9585): 365-6, 2007.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17678998&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17678998&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.72">Shastri SS, Mittra I, Mishra GA, et al.: 
Effect of VIA screening by primary health workers: randomized controlled
 study in Mumbai, India. J Natl Cancer Inst 106 (3): dju009, 2014.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24563518&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24563518&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.73">Brewster WR, Hubbell FA, Largent J, et al.: 
Feasibility of management of high-grade cervical lesions in a single 
visit: a randomized controlled trial. JAMA 294 (17): 2182-7, 2005.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16264159&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16264159&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.74">Zhao FH, Lewkowitz AK, Chen F, et al.: Pooled 
analysis of a self-sampling HPV DNA Test as a cervical cancer primary 
screening method. J Natl Cancer Inst 104 (3): 178-88, 2012.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22271765&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22271765&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
    <li id="section_2.75">Denny L, Kuhn L, De Souza M, et al.: 
Screen-and-treat approaches for cervical cancer prevention in 
low-resource settings: a randomized controlled trial. JAMA 294 (17): 
2173-81, 2005.&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16264158&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16264158&amp;dopt=Abstract">[PUBMED Abstract]</a></li>
  </ol>
</section>
	</div>
</div>
      </article>
      
      <div id="cgvBackToTop">
	<div class="contentid-909235 slot-item only-SI">
		<p><a class="backtotop-link" href="#top"><img alt="Back to Top" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/backtotop_red.gif" border="0">Back to Top</a></p>
	</div>
</div>
      <div id="cgvDate">
	<div class="contentid-1513 slot-item only-SI">
		




<div class="document-dates">
<ul class="clearfix">
<li><strong>Updated:</strong> February
 12, 2015</li>
</ul>
</div>

	</div>
</div>
      <div id="cgvBodyNav">
	<div class="contentid-909235 slot-item only-SI">
		<p><a href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page1">&lt; Previous Section</a>&nbsp;&nbsp;<span class="navigation-gray">|</span>&nbsp;&nbsp;<a href="http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page3">Next Section &gt;</a></p>

	</div>
</div>
      
      
      <!-- Begin Public Use Slot -->
      <div id="cgvPublicUseNoticeSl">
	<div class="contentid-260294 slot-item only-SI">
		
	</div>
</div>
      <!-- End Public Use Slot --> 
    </div>
    <!-- End Content Area --> 
  </div>
  <!-- End Left Navigation and Content Area --> 
  <!-- End Main Area --> 
  <!-- Footer -->
  <div id="cgvFooter" removeifempty="false">
	<div class="contentid-36968 slot-item only-SI">
		<!-- BEGIN Footer --><div id="cgvSiteFooter"><ul id="findHelp"><li><a href="http://www.cancer.gov/global/contact" onclick="NCIAnalytics.QuestionsAboutCancerFooter(this);">We Can Answer Your Questions</a></li><li><strong>1-800-4-CANCER</strong></li><li><a href="https://livehelp.cancer.gov/" onclick="javascript:window.open('https://livehelp.cancer.gov/', 'LiveHelp','scrollbars=yes,resizable=yes,menubar=yes,toolbar=yes,location=yes,width=650,height=600'); return false;">LiveHelp Online Chat</a></li></ul><ul id="footerUtility"><li><a href="http://www.cancer.gov/" onclick="NCIAnalytics.FooterLink(this, 'NCI Home');">NCI Home</a></li><li><a href="http://www.cancer.gov/global/contact" onclick="NCIAnalytics.FooterLink(this, 'Contact Us');">Contact Us</a></li><li><a href="http://www.cancer.gov/global/web/policies" onclick="NCIAnalytics.FooterLink(this, 'Policies');">Policies</a></li><li><a href="http://www.cancer.gov/global/web/policies/accessibility" onclick="NCIAnalytics.FooterLink(this, 'Accessibility');">Accessibility</a></li><li><a href="http://www.cancer.gov/global/viewing-files" onclick="NCIAnalytics.FooterLink(this, 'Viewing Files');">Viewing Files</a></li><li><a href="http://www.cancer.gov/global/web/policies/foia" onclick="NCIAnalytics.FooterLink(this, 'FOIA');">FOIA</a></li><li><a href="http://www.cancer.gov/global/web/sitehelp" onclick="NCIAnalytics.FooterLink(this, 'Site Help');">Site Help</a></li><li class="last"><a href="http://www.cancer.gov/global/web/sitemap" onclick="NCIAnalytics.FooterLink(this, 'Site Map');">Site Map</a></li></ul><strong>Follow Us:</strong> <ul id="followUs"><li class="twitter"><a href="http://www.cancer.gov/global/newmedia#twitter" onclick="NCIAnalytics.FooterLink(this, 'Twitter');">Twitter</a></li><li class="youtube"><a class="no-exit-notification" href="http://www.youtube.com/ncigov" onclick="NCIAnalytics.FooterLink(this, 'YouTube');">YouTube</a></li><li class="facebook"><a href="http://www.cancer.gov/global/newmedia#facebook" onclick="NCIAnalytics.FooterLink(this, 'Facebook');">Facebook</a></li><li class="rss"><a href="http://www.cancer.gov/global/RSS" onclick="NCIAnalytics.FooterLink(this, 'RSS');">RSS</a></li></ul><p class="other-versions"><strong>Other Versions: <img nopin="nopin" alt="Mobile" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/icon-mobile.png" style=" vertical-align: top;"></strong> <a class="gray-text" href="http://m.cancer.gov/" onclick="NCIAnalytics.FooterLink(this, 'Mobile');" style=" font-size: 11px;">Mobile</a> | <a class="gray-text" href="http://www.cancer.gov/espanol" onclick="NCIAnalytics.FooterLink(this, 'Espanol');" style=" font-size: 11px;">Español</a></p><ul id="agencyLinks"><li><a href="http://www.hhs.gov/">U.S. Department of Health and Human Services</a></li><li><a href="http://www.nih.gov/">National Institutes of Health</a></li><li><a href="http://www.cancer.gov/">National Cancer Institute</a></li><li class="last"><a href="http://www.usa.gov/">USA.gov</a></li></ul><div class="nih-tagline" style=" font-size: 12px;">NIH…Turning Discovery Into Health<sup>®</sup></div></div><!-- END Footer -->
	</div>
</div>
  <!-- End Foooter--> 
</div><div id="_atssh" style="visibility: hidden; height: 1px; width: 1px; position: absolute; top: -9999px; z-index: 100000;"><iframe src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/sh200.html" style="height: 1px; width: 1px; position: absolute; top: 0px; z-index: 100000; border: 0px none; left: 0px;" title="AddThis utility frame" id="_atssh987"></iframe></div><script src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/core201.js" type="text/javascript"></script>
<!-- End CGovContainer--> 
<!-- TO INSERT WEB ANALYTICS CODE. Every template should have this 
    control else Web analytics scripts will not show up in the HTML-->

<!-- ***** NCI Web Analytics - DO NOT ALTER ***** -->
<script language="JavaScript" type="text/javascript">
<!--
var s_account='nciglobal,ncienglish-all,ncicancertopics,ncipdq';
-->
</script>
<script language="JavaScript" type="text/javascript" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/NCIAnalyticsFunctions.js"></script>
<script language="JavaScript" type="text/javascript" src="Cervical%20Cancer%20Screening%20%28PDQ%C2%AE%29%20-%20National%20Cancer%20Institute_files/s_code.js"></script>
<script language="JavaScript" type="text/javascript">
<!--
s.channel='PDQ Screening/Detection (English)';
s.prop3='/cancertopics/pdq/screening/cervical';
s.prop6='Cervical Cancer Screening (PDQ®)';
s.prop8='english';
s.prop10=document.title;
s.prop25='01/01/1980';
s.prop27='Description of the Evidence';
s.eVar2='english';
s.events='event1';

var s_code=s.t();
if(s_code)
   document.write(s_code);
-->
</script>
<!-- ***** End NCI Web Analytics ***** -->



<script id="f5_cspm">(function(){var f5_cspm={f5_p:'MDFLIEMHENFGEIKHAEKNLFCLECINFAKHCGGMJPJPPGABCPEAHLGEAMHOKFMAIFKAAAJLEFKAHIDDIGLLAANGHLDIHMLBMGIFOBHJNBIIHAHKPMOEBPKELCDFHAJPFDID',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,32,(latency>>8));str=f5_cspm.set_byte(str,33,(latency&0xff));str=f5_cspm.set_byte(str,27,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='f5avraaaaaaaaaaaaaaaa='+encodeURIComponent(cookie_val)+';path=/';}
return;}}
catch(err){return;}
setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'&&pair[1]=='1234')
{var d=new Date();d.setTime(d.getTime()-1000);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;';setTimeout(f5_cspm.wait_perf_data,100);}}}}
f5_cspm.go();}());</script><ul style="z-index: 1; top: 0px; left: 0px; display: none;" aria-activedescendant="ui-active-menuitem" role="listbox" class="ui-autocomplete ui-menu ui-widget ui-widget-content ui-corner-all"></ul></body></html>